Primary vs nodal site PET/CT response as a prognostic marker in oropharyngeal squamous cell carcinoma treated with intensity-modulated radiation therapy.
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
/ diagnostic imaging
Fluorodeoxyglucose F18
Head and Neck Neoplasms
Humans
Middle Aged
Oropharyngeal Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Prognosis
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
Oropharyngeal squamous cell carcinoma (OPSCC)
PET/CT response assessment
head and neck cancers (HNC)
human papilloma virus (HPV)
intensity-modulated radiation therapy (IMRT)
positron emission tomography/computed tomography (PET/CT)
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
10
11
2019
revised:
05
04
2020
accepted:
22
04
2020
pubmed:
12
5
2020
medline:
28
5
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Positron emission tomography/computed tomography (PET/CT) in staging of advanced oropharyngeal squamous cell carcinoma (OPSCC) and at 3 months posttreatment (PETpost) is often utilized to assess response. The significance of lymph node vs primary site treatment response is incompletely understood. We reviewed 230 patients treated with radiation therapy. PETpost response was graded at primary and nodal sites and correlated with survival. Median age was 58, and 83% were p16-positive. Median follow-up was 24.3 months. Nodal response at PETpost predicted improved 2-year local recurrence-free survival (LRFS) (93% vs 72%, P =.004), 2-year disease-free survival (DFS) (80% vs 61.3%, P =.021), and 2-year overall survival (OS) (89% vs 83%, P =.051), while primary response only predicted improved 2-year LRFS (91% vs 76% P = .035). In OPSCC patients, both nodal and primary response at 3 months on PET/CT predicted for improved LRFS, but only nodal response predicted DFS and OS.
Sections du résumé
BACKGROUND
Positron emission tomography/computed tomography (PET/CT) in staging of advanced oropharyngeal squamous cell carcinoma (OPSCC) and at 3 months posttreatment (PETpost) is often utilized to assess response. The significance of lymph node vs primary site treatment response is incompletely understood.
METHODS
We reviewed 230 patients treated with radiation therapy. PETpost response was graded at primary and nodal sites and correlated with survival.
RESULTS
Median age was 58, and 83% were p16-positive. Median follow-up was 24.3 months. Nodal response at PETpost predicted improved 2-year local recurrence-free survival (LRFS) (93% vs 72%, P =.004), 2-year disease-free survival (DFS) (80% vs 61.3%, P =.021), and 2-year overall survival (OS) (89% vs 83%, P =.051), while primary response only predicted improved 2-year LRFS (91% vs 76% P = .035).
CONCLUSION
In OPSCC patients, both nodal and primary response at 3 months on PET/CT predicted for improved LRFS, but only nodal response predicted DFS and OS.
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2405-2413Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Mehanna H, Wong W, McConkey C, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374:1444-1454.
Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31:590-595.
Li P, Zhuang H, Mozley D, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med. 2001;26:131-135.
Sakamoto H, Nakai Y, Ohashi Y, et al. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Acta Oto-Laryngologica. 1998;538:254-260.
Bar-Ad V, Mishra M, Ohri N, Intenzo C. Positron emission tomography for neck evaluation following definitive treatment with Chemoradiotherapy for Locoregionally advanced head and neck squamous cell carcinoma. Rev Recent Clin Trials. 2012;7:36-41.
Isles M, McConkey C, Mehanna H. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210-222.
Moeller B, Rana V, Cannon B, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509-2515.
Gillison M. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
An Y, Holsinger F, Husain Z. De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer. Cancer Head Neck. 2016;1:18.
Hasegawa M, Maeda H, Deng Z, et al. Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer. Int J Oncol. 2014;45:1017-1026.
Chen S, Hsieh T, Yen K, et al. Interim FDGPET/CT for predicting the outcome in patients with head and neck cancer. Laryngoscope. 2014;124:2732-2738.
Pollom E, Song J, Durkee B, et al. Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. Head Neck. 2016;38:1472-1478.
Dequanter D, Shahla M, Aubert C, Deniz Y, Lothaire P. Prognostic value of FDG PET/CT in head and neck squamous cell carcinomas. Onco Targets Ther. 2015;8:2279-2283.
Bird T, Barrington S, Thavaraj S, et al. 18F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015;43:1239-1247.
Cacicedo J, Fernandez I, del Hoyo O, et al. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. Clin Transl Oncol. 2017;19:1337-1349.
Ho A, Tsao G, Chen F, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2012;119:1349-1356.
Vainshtein J, Spector M, Stenmark M, et al. Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014;50:234-239.
Yao M, Smith R, Hoffman H, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-A long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9-14.
Awan M, Lavertu P, Zender C, et al. Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation. Eur J Nucl Med Mol Imaging. 2017;44:988-997.
Koshkareva Y, Branstetter B, Gaughan J, et al. Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. Laryngoscope. 2014;124:1843-1847.
Marcus C, Ciarallo A, Tahari AK, et al. Head and neck PET/CT: therapy response interpretation criteria (Hopkins criteria) - interreader reliability, accuracy, and survival outcomes. J Nucl Med. 2014;55:1411-1416.
Sjövall J, Bitzén U, Kjellén E, Nilsson P, Wahlberg P, Brun E. Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging. 2016;43:609-616.
van Gysen K, Stevens M, Guo L, et al. Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. BMC Cancer. 2019;19:674-681.
Mizumachi T, Homma A, Sakashita T, Kano S, Hatakeyama H, Fukuda S. Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan. Int J Clin Oncol. 2017;22:682-689.